LLY

1,046.75

+2.45%↑

JNJ

244.3

+1.63%↑

ABBV

225.77

+2.42%↑

NVS

161.26

+0.89%↑

MRK

120.13

+1.37%↑

LLY

1,046.75

+2.45%↑

JNJ

244.3

+1.63%↑

ABBV

225.77

+2.42%↑

NVS

161.26

+0.89%↑

MRK

120.13

+1.37%↑

LLY

1,046.75

+2.45%↑

JNJ

244.3

+1.63%↑

ABBV

225.77

+2.42%↑

NVS

161.26

+0.89%↑

MRK

120.13

+1.37%↑

LLY

1,046.75

+2.45%↑

JNJ

244.3

+1.63%↑

ABBV

225.77

+2.42%↑

NVS

161.26

+0.89%↑

MRK

120.13

+1.37%↑

LLY

1,046.75

+2.45%↑

JNJ

244.3

+1.63%↑

ABBV

225.77

+2.42%↑

NVS

161.26

+0.89%↑

MRK

120.13

+1.37%↑

Search

Twist Bioscience Corp

Abierto

SectorSanidad

47.04 -3.49

Resumen

Variación precio

24h

Actual

Mínimo

47.91

Máximo

50.52

Métricas clave

By Trading Economics

Ingresos

-3.4M

-31M

Ventas

4.7M

104M

Margen de beneficios

-29.419

Empleados

979

EBITDA

-3.2M

-24M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+9.54% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

309M

2.9B

Apertura anterior

50.53

Cierre anterior

47.04

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

149 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Twist Bioscience Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 feb 2026, 23:47 UTC

Acciones populares

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 feb 2026, 22:59 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Grab Holdings to Buy U.S.-Based Stash Financial

11 feb 2026, 23:54 UTC

Ganancias

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 feb 2026, 23:50 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

11 feb 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 feb 2026, 23:49 UTC

Ganancias

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 feb 2026, 23:45 UTC

Ganancias

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 feb 2026, 23:42 UTC

Ganancias

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 feb 2026, 23:41 UTC

Ganancias

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 feb 2026, 23:40 UTC

Ganancias

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 feb 2026, 23:35 UTC

Charlas de Mercado

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 feb 2026, 23:18 UTC

Charlas de Mercado

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 feb 2026, 23:14 UTC

Charlas de Mercado

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 feb 2026, 22:59 UTC

Ganancias

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 feb 2026, 22:59 UTC

Ganancias

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 feb 2026, 22:59 UTC

Ganancias

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 feb 2026, 22:58 UTC

Ganancias

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 feb 2026, 22:57 UTC

Ganancias

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 feb 2026, 22:54 UTC

Ganancias

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 feb 2026, 22:53 UTC

Ganancias

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 feb 2026, 22:47 UTC

Ganancias

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 feb 2026, 22:47 UTC

Ganancias

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 feb 2026, 22:23 UTC

Ganancias

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 feb 2026, 22:22 UTC

Ganancias

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 feb 2026, 22:22 UTC

Ganancias

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 feb 2026, 22:19 UTC

Ganancias

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 feb 2026, 22:18 UTC

Ganancias

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 feb 2026, 22:18 UTC

Ganancias

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 feb 2026, 22:18 UTC

Ganancias

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 feb 2026, 22:16 UTC

Ganancias

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Comparación entre iguales

Cambio de precio

Twist Bioscience Corp previsión

Precio Objetivo

By TipRanks

9.54% repunte

Estimación a 12 Meses

Media 52 USD  9.54%

Máximo 58 USD

Mínimo 50 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Twist Bioscience Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

6

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

31.56 / 38.6884Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

149 / 352 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.